GleamWall
中文EN

NXTC NextCure, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661059 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY71.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-281.1%
ROA-166.2%
ROIC (approx.)-505.2%
Asset turnover—

Leverage & solvency

Liabilities / assets43.3%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$4.54M$7.42M$6.83M$6.80M$6.14M$24.09M$7.90M$8.90M
SG&A expense$4.43M$2.59M$3.27M$2.96M$2.81M$3.20M$3.73M$3.55M
Operating income-$6.92M-$15.09M-$10.11M-$9.76M-$8.95M-$27.29M-$11.62M-$12.46M
Income tax$0$0$0$0$0$0$0—
Net income-$6.85M-$14.89M-$9.80M-$9.44M-$8.62M-$26.81M-$10.98M-$11.60M
EPS (basic)-1.29-2.80-1.87—-3.22-11.29-4.70—
EPS (diluted)-1.29-2.80-1.87—-3.22-11.29-4.70—
Weighted avg. shares (diluted)5.31M5.31M5.24M—2.68M2.37M2.33M—
Balance sheet
Cash & equivalents$8.73M$15.26M$15.17M$25.98M$7.32M$4.89M$21.83M$27.73M
Current assets$9.70M$22.25M$31.74M$43.75M$32.64M$40.02M$58.90M$71.81M
PP&E, net—$283,000$2.99M$3.27M$3.64M$4.17M$4.80M$5.46M
Total assets$9.70M$22.62M$37.98M$50.18M$39.61M$47.69M$67.14M$80.86M
Current liabilities$4.20M$6.41M$6.89M$10.57M$10.99M$10.78M$5.74M$9.57M
Total liabilities$4.20M$10.47M$11.26M$15.24M$15.97M$16.04M$11.28M$15.39M
Shareholders' equity$5.50M$12.15M$26.72M$34.94M$23.65M$29.65M$55.85M$65.47M
Shares outstanding4.58M4.07M3.61M3.51M2.68M2.34M28.01M2.33M
Cash flow statement
Operating cash flow-$12.07M-$9.71M-$13.36M-$7.64M-$6.27M-$22.71M-$12.99M-$6.97M
Capital expenditure———————-$34,000
Free cash flow———————-$6.93M
Investing cash flow$5.54M$9.79M$1.30M$6.00M$8.70M$3.76M$7.09M$6.96M
Financing cash flow$1,000$22,000$1.25M$20.29M$0——$36,000
Stock-based compensation$196,000$304,000$344,000$435,000$600,000$587,000$1.36M$1.52M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.